Navigation Links
MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Date:11/14/2011

GAITHERSBURG, Md., Nov. 14, 2011 /PRNewswire/ -- MedImmune today announced the winners of its 6th Annual Research Abstract Competition highlighting the work of the next generation of scientific leaders performing research in the areas of respiratory, inflammatory and autoimmune (RIA) disease. Graduate students and postdoctoral fellows were invited to submit abstracts about RIA research as part of a competition sponsored by MedImmune, the global biologics arm of AstraZeneca.

First prize of $2,000 was awarded to Philippe LeBlanc of Department of Medicine, McGill University, Montreal, Canada, for his research topic, Caspase-1 processes HMGB1 into an immunogenic peptide that signals through RAGE.

LeBlanc noted, "Thank you to all the friendly staff at MedImmune who organized this conference and provided an important opportunity for academia to interface with the private research sector. Many congratulations and thanks to the other participants for sharing their excellent work."

Second and third prizes of $1,000 and $500 were awarded respectively to Jillian Barlow, Laboratory of Molecular Biology, Medical Research Council, Cambridge, UK, and Xiangping Yang, Ph.D, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.

Launched in 2006, MedImmune's Annual Research Abstract Competition aims to engage emerging scientists in health and science education to cultivate a competitive environment that nurtures future research in key therapeutic areas. In 2009, following the success of the RIA abstract competition in the U.S., MedImmune introduced a similar effort in Europe to acknowledge advances in the field of oncology. Since its inception, the MedImmune Annual Research Competition has received more than 330 research abstracts from across the globe.

"We are continuously impressed with the quality of submissions put forth by these young scientists each year," said Bing Y
'/>"/>

SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Immune Design Grants Adjuvant License to MedImmune
2. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
3. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
4. HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)
5. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
6. MedImmune Announces Zook as President
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
9. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
10. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015 ... osoitteessa  http://www.openinnovationinscience.at Wienissä pidettävään ... Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... tekemän, kansainvälisiä tutkijoita ja tiedemiehiä ... suurinta haastetta ovat kannustimien puute ...
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis ... from 2015 to 2020. The bioscience market is expected to grow at the highest ... of failure analysis equipment in the research labs and academic institutions for root cause ...
(Date:7/3/2015)... 2015 Forskere kan ... in Science", som finner sted i ... nett, på  http://www.openinnovationinscience.at , og søknadsperioden varer ... De to største utfordringene innen helsevitenskapen er ... forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, i ...
(Date:7/3/2015)... , July 3, 2015 ... 22. september 2015 på  http://www.openinnovationinscience.at om ... der finder sted i Wien ... undersøgelse af internationale forskere og videnskabsmænd foretaget ... to største udfordringer for sundhedsvidenskaben manglen på ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... DIEGO , March 16  Neurocrine Biosciences, Inc. (Nasdaq: ... recently completed public offering of common stock has exercised in ... common stock to cover over-allotments.  The sale of the additional ... into account the sale of the additional shares at a ...
... Shire plc (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice Letter,from Teva Pharmaceuticals USA, Inc. ("Teva") advising of ... release tablets,INTUNIV(TM). , ... , ... ...
... LONDON, ON , March 16 /PRNewswire/ ... protein therapeutic, demonstrated positive results in a pivotal proof ... model for arthritis. VT-346 achieved a statistically significant, dose ... prevented deterioration due to disease in terms of weight ...
Cached Biology Technology:Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 2Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 2Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 3Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 4
(Date:6/26/2015)... June 26, 2015 ATL Technology, LLC, a top ... specialties in single use solutions, headquartered in Springville, ... (a California corporation with locations in ... San Jose, Costa Rica ). This acquisition ... with ATL Technology,s existing facility in ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Oslo, April 7, 2010: OptiNose, a leader in ... publication in Cephalalgia of results from its ... of its novel, intranasal drug/device product for the treatment ... and 20mg doses administered intranasally using OptiNose,s bi-directional delivery ...
... to exercise, help may be on the way. That,s ... as exercise, promotes new bone growth. This opens the ... into thinking they are getting a workout. The research ... FASEB Journal ( http://www.fasebj.org ). This ...
... Calif.) African-American women have poorer survival rates ... whether they receive radiation therapy following lumpectomy or ... Martinez, assistant professor of surgery at UC Davis ... women with advanced breast cancer are less likely ...
Cached Biology News:OptiNose's novel intranasal sumatriptan product highly effective in treating migraines 2For osteoporosis patients, exercise pill one step closer to reality 2Disparities persist in outcomes for African-American women with advanced breast cancer 2
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... 3D structure visualization, phylogenetic tree building, sequence ... single application. Retrieve ... and filter them in real-time Organize ... searching, filtering and sorting Provides up-to-date ...
Biology Products: